Kardiologiia 2012-01-01

[Lercanidipine in the treatment of arterial hypertension].

L O Minushkina, I K Iosava

Index: Kardiologiia 52(12) , 70-4, (2012)

Full Text: HTML

Abstract

This review summarizes data on the effectiveness of lercanidipine. Lercanidipine is dihydropyridine calcium antagonist of the third generation, characterized by high vazoselective, long duration of action and good antihypertensive effect. It may be assigned to elderly patients with isolated hypertension and has several important organoprotective properties. Treatment with lercanidipine promotes nephroprotection, reduction of left ventricular hypertrophy, improvement of elastic properties of blood vessels and reduction of central pressure. Sympathetic activation in the application of lercanidipine is virtually absent, that ensures its good tolerability and high adherence of patients to treatment.


Related Compounds

Related Articles:

Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake.

2012-07-01

[Eur. J. Clin. Pharmacol. 68(7) , 1043-7, (2012)]

Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.

2010-01-01

[Clin. Drug Investig. 30(12) , 843-54, (2010)]

Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.

2011-05-01

[Cell. Mol. Neurobiol. 31(4) , 561-7, (2011)]

Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.

2010-09-01

[Clin. Nephrol. 74(3) , 217-22, (2010)]

Polymorphism of the methylenetetrahydrofolate reductase gene C677T and its influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment.

2012-06-01

[Gene 500(2) , 207-10, (2012)]

More Articles...